Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
158 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Anthrax - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Anthrax - Pipeline Review, H2 2014', provides an overview of the Anthrax's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Anthrax, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anthrax and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Anthrax - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Anthrax and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Anthrax products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Anthrax pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Anthrax - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Anthrax pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Anthrax Overview 8 Therapeutics Development 9 Pipeline Products for Anthrax - Overview 9 Pipeline Products for Anthrax - Comparative Analysis 10 Anthrax - Therapeutics under Development by Companies 11 Anthrax - Therapeutics under Investigation by Universities/Institutes 14 Anthrax - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Anthrax - Products under Development by Companies 18 Anthrax - Products under Investigation by Universities/Institutes 21 Anthrax - Companies Involved in Therapeutics Development 22 Aradigm Corporation 22 Bavarian Nordic A/S 23 Bristol-Myers Squibb Company 24 Cellceutix Corporation 25 ContraFect Corporation 26 Dynavax Technologies Corporation 27 Elusys Therapeutics, Inc. 28 Emergent BioSolutions Inc. 29 Evolva SA 30 Green Cross Corporation 31 Grifols, S.A. 32 Hawaii Biotech, Inc. 33 iBio, Inc. 34 Immunovaccine, Inc. 35 Innovative Biologics, Inc. 36 Microbiotix, Inc. 37 NanoBio Corporation 38 Navigen Pharmaceuticals, Inc. 39 Oragenics, Inc. 40 PaxVax 41 Pfenex Inc. 42 Planet Biotechnology Inc. 43 Protein Potential, LLC 44 ProThera Biologics, LLC. 45 PsiOxus Therapeutics, Ltd. 46 Revivicor, Inc. 47 SelectX Pharmaceuticals, Inc. 48 Soligenix, Inc. 49 Summit Corporation plc 50 Syntiron LLC 51 Tetraphase Pharmaceuticals Inc. 52 The Medicines Company 53 Vaxin, Inc. 54 Anthrax - Therapeutics Assessment 55 Assessment by Monotherapy Products 55 Assessment by Combination Products 56 Assessment by Target 57 Assessment by Mechanism of Action 59 Assessment by Route of Administration 61 Assessment by Molecule Type 63 Drug Profiles 65 anthrax + plague vaccine - Drug Profile 65 anthrax vaccine - Drug Profile 66 anthrax vaccine - Drug Profile 68 anthrax vaccine - Drug Profile 69 anthrax vaccine - Drug Profile 70 anthrax vaccine - Drug Profile 71 anthrax vaccine - Drug Profile 72 anthrax vaccine - Drug Profile 73 anthrax vaccine - Drug Profile 74 anthrax vaccine - Drug Profile 76 anthrax vaccine next generation - Drug Profile 77 ARD-3100 - Drug Profile 78 AV-7909 - Drug Profile 80 CF-307 - Drug Profile 81 CF-308 - Drug Profile 82 ciprofloxacin hydrochloride - Drug Profile 83 DV-230 - Drug Profile 84 EV-021 - Drug Profile 85 GC-1109 - Drug Profile 86 GREANX - Drug Profile 87 Human Antibody Based Vaccines - Drug Profile 88 KKL-35 - Drug Profile 90 MDX-1303 - Drug Profile 91 Monoclonal Antibody for Respiratory Anthrax - Drug Profile 93 Monoclonal Antibody to Inhibit Anthrax Protective Antigen for Anthrax - Drug Profile 94 MU-1140 - Drug Profile 95 MVA-BN Anthrax - Drug Profile 97 NP-015 - Drug Profile 98 obiltoxaximab - Drug Profile 99 oritavancin diphosphate - Drug Profile 101 PBI-220 - Drug Profile 104 PMX-30016 - Drug Profile 106 PreviThrax - Drug Profile 107 Proteins to Inhibit Furin for Anthrax Intoxication and Sepsis - Drug Profile 109 Px-563L - Drug Profile 110 RiVax + VeloThrax - Drug Profile 111 Second Generation Px-563L - Drug Profile 112 SGX-204 - Drug Profile 113 Slit2N - Drug Profile 114 Small Molecule to Agonize TLR for Anthrax - Drug Profile 116 Small Molecule to Inhibit Anthrax Toxin for Anthrax - Drug Profile 117 Small Molecules for Bacterial Infections - Drug Profile 118 Small Molecules to Inhibit Anthrax Lethal Factor Toxin for Anthrax - Drug Profile 119 Small Molecules to Inhibit Lethal Factor for Anthrax - Drug Profile 120 Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis - Drug Profile 122 Small Molecules to Inhibit MMP - Drug Profile 123 SMT-15000 - Drug Profile 124 TP-271 - Drug Profile 125 Anthrax - Recent Pipeline Updates 127 Anthrax - Dormant Projects 141 Anthrax - Discontinued Products 142 Anthrax - Product Development Milestones 143 Featured News & Press Releases 143 Appendix 153 Methodology 153 Coverage 153 Secondary Research 153 Primary Research 153 Expert Panel Validation 153 Contact Us 154 Disclaimer 154
List of Tables Number of Products under Development for Anthrax, H2 2014 13 Number of Products under Development for Anthrax - Comparative Analysis, H2 2014 14 Number of Products under Development by Companies, H2 2014 16 Number of Products under Development by Companies, H2 2014 (Contd..1) 17 Number of Products under Investigation by Universities/Institutes, H2 2014 18 Comparative Analysis by Late Stage Development, H2 2014 19 Comparative Analysis by Clinical Stage Development, H2 2014 20 Comparative Analysis by Early Stage Development, H2 2014 21 Products under Development by Companies, H2 2014 22 Products under Development by Companies, H2 2014 (Contd..1) 23 Products under Development by Companies, H2 2014 (Contd..2) 24 Products under Investigation by Universities/Institutes, H2 2014 25 Anthrax - Pipeline by Aradigm Corporation, H2 2014 26 Anthrax - Pipeline by Bavarian Nordic A/S, H2 2014 27 Anthrax - Pipeline by Bristol-Myers Squibb Company, H2 2014 28 Anthrax - Pipeline by Cellceutix Corporation, H2 2014 29 Anthrax - Pipeline by ContraFect Corporation, H2 2014 30 Anthrax - Pipeline by Dynavax Technologies Corporation, H2 2014 31 Anthrax - Pipeline by Elusys Therapeutics, Inc., H2 2014 32 Anthrax - Pipeline by Emergent BioSolutions Inc., H2 2014 33 Anthrax - Pipeline by Evolva SA, H2 2014 34 Anthrax - Pipeline by Green Cross Corporation, H2 2014 35 Anthrax - Pipeline by Grifols, S.A., H2 2014 36 Anthrax - Pipeline by Hawaii Biotech, Inc., H2 2014 37 Anthrax - Pipeline by iBio, Inc., H2 2014 38 Anthrax - Pipeline by Immunovaccine, Inc., H2 2014 39 Anthrax - Pipeline by Innovative Biologics, Inc., H2 2014 40 Anthrax - Pipeline by Microbiotix, Inc., H2 2014 41 Anthrax - Pipeline by NanoBio Corporation, H2 2014 42 Anthrax - Pipeline by Navigen Pharmaceuticals, Inc., H2 2014 43 Anthrax - Pipeline by Oragenics, Inc., H2 2014 44 Anthrax - Pipeline by PaxVax, H2 2014 45 Anthrax - Pipeline by Pfenex Inc., H2 2014 46 Anthrax - Pipeline by Planet Biotechnology Inc., H2 2014 47 Anthrax - Pipeline by Protein Potential, LLC, H2 2014 48 Anthrax - Pipeline by ProThera Biologics, LLC., H2 2014 49 Anthrax - Pipeline by PsiOxus Therapeutics, Ltd., H2 2014 50 Anthrax - Pipeline by Revivicor, Inc., H2 2014 51 Anthrax - Pipeline by SelectX Pharmaceuticals, Inc., H2 2014 52 Anthrax - Pipeline by Soligenix, Inc., H2 2014 53 Anthrax - Pipeline by Summit Corporation plc, H2 2014 54 Anthrax - Pipeline by Syntiron LLC, H2 2014 55 Anthrax - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2014 56 Anthrax - Pipeline by The Medicines Company, H2 2014 57 Anthrax - Pipeline by Vaxin, Inc., H2 2014 58 Assessment by Monotherapy Products, H2 2014 59 Assessment by Combination Products, H2 2014 60 Number of Products by Stage and Target, H2 2014 62 Number of Products by Stage and Mechanism of Action, H2 2014 64 Number of Products by Stage and Route of Administration, H2 2014 66 Number of Products by Stage and Molecule Type, H2 2014 68 Anthrax Therapeutics - Recent Pipeline Updates, H2 2014 131 Anthrax - Dormant Projects, H2 2014 145 Anthrax - Discontinued Products, H2 2014 146
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
